Navigation Links
Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology

SOUTH SAN FRANCISCO, Calif., Nov. 25 /PRNewswire/ -- Proteolix, Inc., a leader in the discovery and development of novel therapeutics that target protein degradation pathways in cancer and autoimmune diseases, today announced that data from two ongoing Phase 2 clinical trials of carfilzomib in multiple myeloma will be presented at the upcoming 50th Annual Meeting of the American Society of Hematology (ASH). Carfilzomib is the first in a new class of specific proteasome inhibitors and is currently in multiple clinical trials for hematologic malignancies and solid tumors. This year's ASH conference will be held December 6-9, 2008 at the George Moscone Center in San Francisco, California.

Sundar Jagannath, M.D., Chief of the Multiple Myeloma Program, Bone Marrow and Blood Stem Cell Transplantation at St. Vincent's Comprehensive Cancer Center in New York will present initial results from Proteolix's Phase 2 study of carfilzomib for the treatment of patients with relapsed and refractory multiple myeloma during the Novel Therapies for Myeloma and Related Disorders session at 7:00 a.m. on Tuesday, December 9, 2008. This ongoing Phase 2 trial is an open-label multi-center study of single-agent carfilzomib in patients who have previously failed at least two prior treatments, containing bortezomib and either lenalidomide or thalidomide, and are refractory to their last treatment. Data from a second ongoing Phase 2 clinical trial of single-agent carfilzomib in relapsed multiple myeloma patients (stratified by prior therapy with bortezomib) will be presented immediately thereafter at 7:15 a.m. by Ravi Vij, M.D., Associate Professor of Medicine, Division of Oncology, Section of Bone Marrow Transplantation, Washington University School of Medicine.

In addition to the oral presentations, the company will have several poster presentations highlighting the results of preclinical studies that further characterize the mechanism and safety profile of carfilzomib. Proteolix will also have a poster presentation on the preclinical pharmacology and characterization of its oral proteasome inhibitor known as PR-047.

A complete list of the company's oral and poster presentations at the ASH meeting follows:

    Oral Presentations -- Tuesday, December 9, 2008
      Session:  Novel Therapies for Myeloma and Related Disorders
      --  7:00 a.m. PST: Initial Results of PX-171-003, An Open-Label,
          Single-Arm, Phase II Study of Carfilzomib (CFZ) in Patients with
          Relapsed and Refractory Multiple Myeloma (MM) (Abstract #864)
      --  7:15 a.m. PST: Initial Results of PX-171-004, An Open-Label,
          Single-Arm, Phase II Study of Carfilzomib (CFZ) in Patients with
          Relapsed Myeloma (MM) (Abstract #865)
      Location: Moscone Center, Gateway Ballroom 103-South

    Poster Presentations
    Sunday, December 7, 2008, 6:00 p.m. -- 8:00 p.m. PST
      Session: Molecular Pharmacology, Drug Resistance Poster II
      --  Non-Proteasomal Targets of Proteasome Inhibitors Bortezomib and
          Carfilzomib (Abstract #2657)
      Session: Myeloma -- Pathophysiology and Preclinical Studies Excluding
       Therapy Poster II
      --  The Selective Proteasome Inhibitor Carfilzomib is Well Tolerated in
          Experimental Animals with Dose Intensive Administration (Abstract
      Location: Moscone Center Hall A

    Monday, December 8, 2008, 5:30 p.m. -- 7:30 p.m. PST
      Session: Myeloma -- Pathophysiology and Preclinical Studies Excluding
       Therapy Poster III
      --  Induction of Sustained Early G1 Arrest by Selective Inhibition of
          CDK4 and CDK6 Primes Myeloma Cells for Synergistic Killing by
          Proteasome Inhibitors Carfilzomib and PR-047 (Abstract #3670)
      --  Preclinical Pharmacology and in vitro Characterization of PR-047, An
          Oral Inhibitor of the 20S Proteasome (Abstract #3671)
      Location: Moscone Center Hall A

About Proteolix

Proteolix, Inc. is a privately-held biopharmaceutical company, headquartered in South San Francisco, dedicated to discovering, developing and commercializing novel therapeutics that target protein degradation pathways for cancer and autoimmune diseases. Proteolix's lead product, carfilzomib (PR-171), the first in a new class of highly specific proteasome inhibitors, is currently in multiple Phase 2 clinical studies to evaluate its safety and efficacy in hematologic and solid tumor malignancies. Proteolix is also developing a pipeline of novel proteasome inhibitors, including an oral proteasome inhibitor and a selective immunoproteasome inhibitor. For additional information on Proteolix, please visit

     Contact information
     Investors:                      Media Inquiries:
     Matthew Ferguson                BCC Partners
     Chief Financial Officer         Karen L. Bergman or Michelle Corral
     650-266-2825                    650-575-1509 or 415-794-8662

SOURCE Proteolix, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
2. Proteolix Initiates Multicenter Open-label Study of the Safety and Activity of Carfilzomib in Subjects With Relapsed Solid Tumors
3. Proteolix Initiates Phase 2 Clinical Trial of Carfilzomib in Patients With Relapsed Solid Tumors
4. Proteolix Initiates Phase 1b Clinical Trial of Carfilzomib in a Combination Regimen for Patients With Relapsed Multiple Myeloma
5. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
6. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
7. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
8. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
9. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
10. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
11. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
Post Your Comments:
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on ... today announced that patient enrollment in its ongoing ... Duchenne) has exceeded 50% of its 24-patient target. ... in the third quarter of 2016, and to ...
(Date:6/23/2016)... the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations headquartered in Bogota. Colombia ... ... Sandra ... ... Astellas is a pharmaceutical company ...
(Date:6/23/2016)... , June 23, 2016  Experian Health, ... and transforming the patient payment and care ... innovative new products and services that will ... revenue cycle offerings. These award-winning solutions will ... workflows, remain compliant in an ever-changing environment ...
Breaking Medicine Technology:
(Date:6/26/2016)... , ... June 26, 2016 , ... PawPaws brand ... new product that was developed to enhance the health of felines. The formula is ... The two main herbs in the PawPaws Cat Kidney Support Supplement Soft ...
(Date:6/25/2016)... , ... June 25, 2016 , ... Austin residents seeking ... American College of Mohs Surgery and to Dr. Russell Peckham for medical and surgical ... effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern ... Laude and his M.D from the David Geffen School of Medicine at UCLA. He ... Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article ... people are unfamiliar with. The article goes on to state that individuals are now ... of these less common operations such as calf and cheek reduction. The Los Angeles ...
(Date:6/24/2016)... ... 2016 , ... The Pulmonary Hypertension Association (PHA) learned during ... two significant new grants to support its work to advance research and patient ... recognizing patients, medical professionals and scientists for their work in fighting pulmonary hypertension ...
Breaking Medicine News(10 mins):